Brokers Set Expectations for LENZ Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:LENZ)

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Equities research analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for shares of LENZ Therapeutics in a research report issued on Monday, April 15th. Leerink Partnrs analyst M. Goodman forecasts that the company will post earnings per share of ($0.51) for the quarter. Leerink Partnrs has a “Outperform” rating on the stock. Leerink Partnrs also issued estimates for LENZ Therapeutics’ Q2 2024 earnings at ($0.47) EPS, Q3 2024 earnings at ($0.40) EPS, Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.80) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($1.30) EPS, FY2027 earnings at $0.85 EPS and FY2028 earnings at $2.70 EPS.

LENZ has been the subject of a number of other research reports. Piper Sandler started coverage on shares of LENZ Therapeutics in a research report on Wednesday, March 27th. They issued an “overweight” rating and a $28.00 target price for the company. William Blair assumed coverage on LENZ Therapeutics in a research report on Monday. They issued an “outperform” rating on the stock. Citigroup assumed coverage on LENZ Therapeutics in a research report on Wednesday, April 10th. They set a “buy” rating and a $34.00 price target for the company. Finally, SVB Leerink initiated coverage on LENZ Therapeutics in a research report on Monday. They set an “outperform” rating and a $32.00 price target on the stock. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, LENZ Therapeutics presently has an average rating of “Buy” and an average price target of $31.33.

LENZ Therapeutics Price Performance

Shares of LENZ opened at $17.49 on Wednesday. The company has a market cap of $145.52 million, a PE ratio of -1.12 and a beta of 0.20. LENZ Therapeutics has a twelve month low of $14.07 and a twelve month high of $29.82.

Insider Activity

In other LENZ Therapeutics news, Director Ra Capital Management, L.P. bought 998,009 shares of the firm’s stock in a transaction that occurred on Thursday, March 21st. The shares were acquired at an average cost of $15.03 per share, with a total value of $15,000,075.27. Following the acquisition, the director now owns 3,319,339 shares of the company’s stock, valued at $49,889,665.17. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 38.40% of the stock is owned by insiders.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.